CGT

29개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved29 programs
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-C182A cells (LCAR-C182A cells)

Gastric Cancer; Pancreatic Ductal Adenocarcinoma · Gastric Cancer

#GastricCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-C18S cells (LCAR-C18S cells)

Solid Tumors, Adult · Solid Tumors, Adult

#SolidTumorsAdult#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-G08 cells (LCAR-G08 cells)

Advanced Gastrointestinal Tumors · Advanced Gastrointestinal Tumors

#AdvancedGastrointestinalTumors#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-G79 T cells (LUCAR-G79 T cells)

Relapsed/Refractory Autoimmune Diseases · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleGilead SciencesPhase 1

NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 (NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1)

Multiple Myeloma; Melanoma · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleMustang BioPreclinical

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleMustang BioPreclinical

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

anti-CD123 CAR-T treatment (anti-CD123 CAR-T treatment)

Acute Leukemia; Acute Leukemia in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued

2 / 2 pages

← PreviousNext →